PALI vs. CELZ, TTNP, NSTGQ, FRTX, IKT, SRNE, PSTV, ONVO, TCON, and FNCH
Should you be buying Palisade Bio stock or one of its competitors? The main competitors of Palisade Bio include Creative Medical Technology (CELZ), Titan Pharmaceuticals (TTNP), NanoString Technologies (NSTGQ), Fresh Tracks Therapeutics (FRTX), Inhibikase Therapeutics (IKT), Sorrento Therapeutics (SRNE), Plus Therapeutics (PSTV), Organovo (ONVO), TRACON Pharmaceuticals (TCON), and Finch Therapeutics Group (FNCH). These companies are all part of the "medical" sector.
Palisade Bio (NASDAQ:PALI) and Creative Medical Technology (NASDAQ:CELZ) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their community ranking, media sentiment, earnings, profitability, risk, analyst recommendations, dividends, valuation and institutional ownership.
Creative Medical Technology has lower revenue, but higher earnings than Palisade Bio. Creative Medical Technology is trading at a lower price-to-earnings ratio than Palisade Bio, indicating that it is currently the more affordable of the two stocks.
11.8% of Palisade Bio shares are held by institutional investors. Comparatively, 1.4% of Creative Medical Technology shares are held by institutional investors. 2.2% of Palisade Bio shares are held by insiders. Comparatively, 3.3% of Creative Medical Technology shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
In the previous week, Creative Medical Technology had 4 more articles in the media than Palisade Bio. MarketBeat recorded 10 mentions for Creative Medical Technology and 6 mentions for Palisade Bio. Creative Medical Technology's average media sentiment score of 0.68 beat Palisade Bio's score of 0.38 indicating that Creative Medical Technology is being referred to more favorably in the news media.
Palisade Bio presently has a consensus price target of $22.50, indicating a potential upside of 248.30%. Given Palisade Bio's higher probable upside, equities research analysts plainly believe Palisade Bio is more favorable than Creative Medical Technology.
Palisade Bio has a beta of 1.25, meaning that its share price is 25% more volatile than the S&P 500. Comparatively, Creative Medical Technology has a beta of 2.22, meaning that its share price is 122% more volatile than the S&P 500.
Creative Medical Technology received 63 more outperform votes than Palisade Bio when rated by MarketBeat users. Likewise, 68.93% of users gave Creative Medical Technology an outperform vote while only 44.44% of users gave Palisade Bio an outperform vote.
Creative Medical Technology's return on equity of -46.50% beat Palisade Bio's return on equity.
Summary
Creative Medical Technology beats Palisade Bio on 11 of the 16 factors compared between the two stocks.
Get Palisade Bio News Delivered to You Automatically
Sign up to receive the latest news and ratings for PALI and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding PALI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Palisade Bio Competitors List
Related Companies and Tools
